Stephen Strickland, MD, Sarah Cannon Research Institute, AML patient and neurologist Dr Joseph, and patient advocate Steve Buechler discuss the critical role of molecular and genetic testing in personalizing treatment for acute myeloid leukemia (AML). They emphasize that identifying specific mutations, including FLT3, NPM1, and IDH, can guide clinicians in the selection of targeted therapies and prediction of patient outcomes. The importance of minimal residual disease monitoring in assessing treatment efficacy and making informed decisions about subsequent therapies is also discussed.